All posts on October, 2015


Underlying processes of working memory more complex than previously thought, say researchers

In order to retain a piece of information for a short time, working memory is required. The underlying processes are considerably more complex than hitherto assumed, as researchers from the Ruhr-Universität Bochum and Bonn University report in the journal “Cell Reports”. Two brain states must alternate rhythmically in order for a piece of information to be successfully maintained.

Read more 0 Comments
Medical research

Hypoxia-inducible factor-1 dependent nuclear entry of factor inhibiting HIF-1

The role of FIH-1 in the regulation of HIF-1 transcriptional activity has been known for some time, but is limited to the understanding that in the nucleus FIH-1 hydrolyzes asparagine at the C-terminus of HIF-1α to prevent the interaction between HIF-1α and associated cofactors, resulting in suppressed activation of HIF-1. FIH-1 is a cytoplasmic protein. When does FIH-1 move into the nucleus? This was specifically addressed in Dr. Y. James Kang’s laboratory in the Regenerative Medicine Research Center at Sichuan University in China and is reported in the November 2015 issue of Experimental Biology and Medicine.

Read more 0 Comments

ISCT launches publication and reference guide on Use of Unproven Cellular Therapies

The International Society for Cellular Therapy, the global society of clinicians, researchers, regulators, technologists, and industry partners dedicated to the translation of cellular therapy into safe and effective therapies to improve patients’ lives, today announces the launch of its publication and reference guide on the Use of Unproven Cellular Therapies.

Read more 0 Comments

First patient of U.S. phase 1 trial treated with Genticel’s GTL001 candidate for HPV 16/18 infections

Genticel, a clinical-stage biotechnology company and developer of innovative immunotherapies to prevent cancers caused by the human papillomavirus, today announces that the first patient of the U.S. phase 1 clinical trial has been vaccinated with GTL001, the company’s first-in-class therapeutic vaccine candidate against HPV 16/18 infections.

Read more 0 Comments